5-Fluorouracil (FUra) and Folinic Acid (FA) Therapy in Patients with Colorectal Cancer
Colorectal cancer is the third most common cancer in North America today (1). Whereas surgery is the mainstay of primary therapy for this disease, it cures on average only 50% of all patients who develop this disease(2). The impact of surgery is greatest at the early stages of this cancer. When the tumour has penetrated to serosa or metastasized to local or distant sites the probability of cure with surgery alone is decreased markedly. In attempts to improve the prognosis for patients in this latter category, new therapies are constantly tested in the metastatic setting(3) and some are investigated in the adjuvant setting(4). We have performed a randomized trial comparing FUra to FUra and FA in patients with previously untreated metastatic colorectal cancer(5). I will describe this study and an ongoing trial of this combination in the adjuvant treatment of patients who have undergone curative resection of the colon.
KeywordsColorectal Cancer Oral Mucositis Adjuvant Setting FOLINIC Acid Muscularis Propria
Unable to display preview. Download preview PDF.
- 1.Silverberg, E., Lubera, J.A., 1968, Cancer Statistics 1988, Ca- A Cancer Journal for Clinicians, 38: 5.Google Scholar
- 2.Surgarbaker, P., Gunderson, L.L., Wittes, R.E., 1985, Colorectal Cancer, in: Cancer Principles and Practices of Oncology, DeVita, V.T., Helleman, S., Rosenberg, S.A. ed. Lippincott Co., Toronto, 795–884.Google Scholar
- 7.Clark, P.I., Slevin, M.L., 1985, Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity, Europ. J. Surg. Oncol., 11: 267.Google Scholar